Adagene Inc ADR Dossier
Qualitative Analysis
Business overview
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The company leverages computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. Powered by its proprietary Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, Adagene is developing a highly differentiated pipeline of immunotherapies. Its lead clinical program, muzastotug (ADG126), is a masked, anti-CTLA-4 SAFEbody with FDA Fast Track designation that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment. This technology is designed to deliver powerful anti-tumor activity with a significantly improved therapeutic index and reduced systemic toxicity compared to first-generation CTLA-4 inhibitors.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the clinical development of lead asset muzastotug (ADG126), a masked anti-CTLA-4 SAFEbody, through a randomized Phase 2 dose-optimization study in microsatellite stable colorectal cancer (MSS CRC) under FDA Project Optimus.
Expected impact: Establishment of an optimized therapeutic index and dose regimen to support initiation of a registrational Phase 3 trial.
Leveraging the proprietary SAFEbody precision masking technology platform to secure strategic partnerships, out-licensing agreements, and collaborations with global biopharmaceutical companies.
Expected impact: Generates non-dilutive funding through upfront payments, option fees, development milestones, and future royalties while validating the platform.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Supports the clinical development of muzastotug (ADG126) in MSS CRC and advanced solid tumors, while utilizing Adagene's SAFEbody platform for a third bispecific antibody discovery program.
Terms: Strategic investment of up to $25 million in Adagene, plus option exercise fees, downstream milestones, and royalties for the discovery program.
Evaluates the combination of muzastotug (ADG126) and Incyte's TGFβR2 x PD-1 bispecific antibody (INCA33890) in 3L MSS CRC patients, validating muzastotug as a potential backbone therapy.
Terms: Incyte will sponsor and conduct the Phase 1 study; Adagene will provide clinical supply of muzastotug.
Third Arc Bio will utilize Adagene's SAFEbody technology platform to generate masked CD3 T cell engagers against unique tumor-associated antigens.
Terms: $5 million upfront payment to Adagene, eligibility for up to $840 million in development and commercial milestones, plus royalties. Adagene retains a no-cost option to develop and commercialize candidates in Greater China, Singapore, and South Korea.